Amlodipine/valsartan/hydrochlorothiazide triple combination therapy in moderate/severe hypertension: Secondary analyses evaluating efficacy and safety

被引:0
作者
David A. Calhoun
Nora A. Crikelair
Joseph Yen
Robert D. Glazer
机构
[1] University of Alabama at Birmingham,Sleep/Wake Disorders Center, Vascular Biology and Hypertension Program
[2] Novartis Pharmaceuticals Corporation,undefined
来源
Advances in Therapy | 2009年 / 26卷
关键词
amlodipine; antihypertensive; blood pressure; combination; dual therapy; hydrochlorothiazide; hypertension; triple therapy; valsartan;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:1012 / 1023
页数:11
相关论文
共 76 条
[21]  
Brunel P.(2002)Factors influencing the systolic blood pressure response to drug therapy J Clin Hypertens (Greenwich) 4 35-40
[22]  
Lacourcière Y.(2004)British Hypertension Society guidelines for hypertension management 2004 (BHS-IV): summary BMJ 328 634-640
[23]  
Poirier L.(2005)Early and aggressive treatment of complex hypertension J Clin Hypertens (Greenwich) 7 8-10
[24]  
Hebert D.(2004)Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial Lancet 363 2049-2051
[25]  
Oparil S.(2006)The importance of early antihypertensive efficacy: the role of angiotensin II receptor blocker therapy J Hum Hypertens 20 169-175
[26]  
Barr E.(2002)Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol Lancet 359 995-1003
[27]  
Elkins M.(2003)The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial J Hypertens 21 875-886
[28]  
Philipp T.(undefined)undefined undefined undefined undefined-undefined
[29]  
Smith T.R.(undefined)undefined undefined undefined undefined-undefined
[30]  
Glazer R.(undefined)undefined undefined undefined undefined-undefined